AGEX THERAPEUTICS INC (AGE) Fundamental Analysis & Valuation

NYSEARCA:AGE • US00848H2076

11.1 USD
-1.5 (-11.9%)
Last: Mar 26, 2024, 08:04 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This AGE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

AGE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. Both the profitability and financial health of AGE have multiple concerns. AGE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. AGE Profitability Analysis

1.1 Basic Checks

  • AGE had negative earnings in the past year.
  • In the past year AGE has reported a negative cash flow from operations.
AGE Yearly Net Income VS EBIT VS OCF VS FCFAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -5M -10M -15M

1.2 Ratios

  • The Return On Assets of AGE (-115.07%) is worse than 82.31% of its industry peers.
  • AGE's Return On Equity of -166.86% is on the low side compared to the rest of the industry. AGE is outperformed by 69.05% of its industry peers.
Industry RankSector Rank
ROA -115.07%
ROE -166.86%
ROIC N/A
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGE Yearly ROA, ROE, ROICAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 600 800

1.3 Margins

  • AGE's Gross Margin of 50.00% is amongst the best of the industry. AGE outperforms 80.27% of its industry peers.
  • In the last couple of years the Gross Margin of AGE has declined.
  • AGE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
AGE Yearly Profit, Operating, Gross MarginsAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. AGE Health Analysis

2.1 Basic Checks

  • AGE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, AGE has about the same amount of shares outstanding.
  • AGE has a worse debt/assets ratio than last year.
AGE Yearly Shares OutstandingAGE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
AGE Yearly Total Debt VS Total AssetsAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M

2.2 Solvency

  • AGE has an Altman-Z score of 49.65. This indicates that AGE is financially healthy and has little risk of bankruptcy at the moment.
  • AGE has a better Altman-Z score (49.65) than 96.94% of its industry peers.
  • A Debt/Equity ratio of 0.08 indicates that AGE is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.08, AGE is doing worse than 64.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 49.65
ROIC/WACCN/A
WACC9.52%
AGE Yearly LT Debt VS Equity VS FCFAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 10M -10M -20M

2.3 Liquidity

  • A Current Ratio of 0.36 indicates that AGE may have some problems paying its short term obligations.
  • The Current ratio of AGE (0.36) is worse than 96.26% of its industry peers.
  • A Quick Ratio of 0.36 indicates that AGE may have some problems paying its short term obligations.
  • The Quick ratio of AGE (0.36) is worse than 96.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.36
AGE Yearly Current Assets VS Current LiabilitesAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AGE Growth Analysis

3.1 Past

  • The earnings per share for AGE have decreased strongly by -42.31% in the last year.
  • The Revenue has grown by 66.67% in the past year. This is a very strong growth!
  • Measured over the past years, AGE shows a very negative growth in Revenue. The Revenue has been decreasing by -53.63% on average per year.
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Sales Q2Q%600%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGE Yearly Revenue VS EstimatesAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M

More info and screens

Find the best growth stocksShow best growing peers

0

4. AGE Valuation Analysis

4.1 Price/Earnings Ratio

  • AGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGE Price Earnings VS Forward Price EarningsAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGE Per share dataAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AGE Dividend Analysis

5.1 Amount

  • AGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

AGE Fundamentals: All Metrics, Ratios and Statistics

AGEX THERAPEUTICS INC

NYSEARCA:AGE (3/26/2024, 8:04:03 PM)

11.1

-1.5 (-11.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-29
Earnings (Next)05-13
Inst Owners0%
Inst Owner Change0%
Ins Owners43.6%
Ins Owner Change0%
Market Cap421.25M
Revenue(TTM)100.00K
Net Income(TTM)-14.05M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4212.45
P/FCF N/A
P/OCF N/A
P/B 50.03
P/tB 54.14
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.22
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -115.07%
ROE -166.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50%
FCFM N/A
ROA(3y)-291.66%
ROA(5y)-221.72%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.98%
GM growth 5Y-5.52%
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.36
Quick Ratio 0.36
Altman-Z 49.65
F-Score4
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-42.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)66.67%
Revenue growth 3Y-74.12%
Revenue growth 5Y-53.63%
Sales Q2Q%600%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.71%
OCF growth 3YN/A
OCF growth 5YN/A

AGEX THERAPEUTICS INC / AGE FAQ

Can you provide the ChartMill fundamental rating for AGEX THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to AGE.


Can you provide the valuation status for AGEX THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to AGEX THERAPEUTICS INC (AGE). This can be considered as Overvalued.


What is the profitability of AGE stock?

AGEX THERAPEUTICS INC (AGE) has a profitability rating of 1 / 10.


How financially healthy is AGEX THERAPEUTICS INC?

The financial health rating of AGEX THERAPEUTICS INC (AGE) is 2 / 10.